Huntington Cabell Opioid Ruling: Judge Faber Sides With Distributors Again After Fourth Circuit Remand
On Nov. 18, 2026, Judge David Faber issued a 243-page remand decision again rejecting Huntington and Cabell County's $2.5 billion public nuisance case against Cencora, McKesson and Cardinal Health. A third trip to the Fourth Circuit is coming.
Torts Desk··12 min read

The federal judge who tried the first federal opioid bellwether against the three largest drug wholesalers has ruled for them a second time: on Nov. 18, 2026, U.S. District Judge David A. Faber of the Southern District of West Virginia held in a 243-page decision that the City of Huntington and the Cabell County Commission did not prove that AmerisourceBergen (now Cencora), McKesson and Cardinal Health created a public nuisance. The Huntington Cabell opioid ruling comes on remand from a Fourth Circuit decision that had vacated Faber's 2022 judgment and handed the plaintiffs a broader legal standard, so it leaves the $2.5 billion abatement claim at zero again and sends the case back to Richmond for a third time.
The result matters well beyond one Appalachian city and county. Huntington and Cabell were the only West Virginia local governments that kept litigating against the "Big 3" distributors after the 2022 statewide settlement, and their case produced the first published federal appellate holding that over-distribution of a controlled substance can be a public nuisance under West Virginia common law. Faber's remand decision shows how much of that appellate win can be absorbed at the fact-finding stage, through causation and reasonableness findings that an appeals court reviews only for clear error.
What did Judge Faber decide in the Huntington Cabell opioid case?
Faber ruled that the plaintiffs failed to carry their burden on the core elements of a public nuisance claim, even under the standards the Fourth Circuit told him to apply. According to coverage of the decision by WV MetroNews, Mountain State Spotlight, WCHS-TV and Law360, the ruling rests on four findings:
- No unreasonable conduct proven. Faber found the city and county could not show that what the three distributors did was unreasonable. He characterized the plaintiffs' theory as one in which "the volume of opioids distributed was in and of itself unreasonable," and declined to treat volume alone as proof of a nuisance.
- Overprescribing, not diversion, drove the volume. The opinion states that "overprescribing—and not illegal prescribing—drove the volume of opioids coming into Cabell/Huntington," and that the volume was overwhelmingly a feature of the evolving standard of care in medicine. Faber found no "competent evidence" that the pills entered the community through illegal prescribing.
- Diversion was not shown while the drugs were in the distributors' control. Law360's account frames the holding as a finding that the county did not prove the prescription opioids were diverted while the wholesalers controlled them, which places responsibility on downstream prescribers and pharmacies acting as intervening causes.
- Standing and balancing. Faber wrote that "the court finds no reason to alter or reverse its previous ruling on standing," and reassessed the claim by weighing "the danger of harm" against "social utility," the reasonableness balance used in nuisance law.
The practical effect is the same as in 2022: judgment for the defendants, no abatement order and no money.
Background: how the case got from a 2021 bench trial to a 2026 remand
The Huntington and Cabell County cases were filed in 2017 and swept into the national opioid MDL, In re National Prescription Opiate Litigation, MDL No. 2804, before Judge Dan Aaron Polster in the Northern District of Ohio. They were later remanded to West Virginia as one of the first federal bellwether tracks to go to trial. The distributors agreed to a bench trial rather than a jury, leaving public nuisance as the central claim. Trial began in May 2021.
The plaintiffs, led by Paul T. Farrell Jr., argued that the three companies shipped about 81 million opioid pills into Huntington and Cabell County between 2006 and 2014, an area with fewer than 100,000 residents. Their abatement plan, built by Johns Hopkins pharmacoepidemiologist Caleb Alexander, called for 15 years of treatment, harm reduction, family services and first-responder support, priced by a forensic economist at about $2.5 billion. McKesson's counsel disputed the 81 million figure at trial, and the distributors blamed rising prescriptions and diversion by others.
| Date | Event | Result |
|---|---|---|
| May 2021 | Bench trial opens before Judge Faber (S.D. W. Va.) | Public nuisance claim tried without a jury |
| July 4, 2022 | Faber's first decision | Judgment for distributors; abatement treated as barred money damages |
| Aug. 2022 | Other West Virginia cities and counties settle with the Big 3 | $400 million over 12 years; Huntington and Cabell excluded |
| 2024 | Fourth Circuit certifies the nuisance question to the Supreme Court of Appeals of West Virginia | State court asked whether distribution can be a public nuisance |
| May 12, 2025 | State high court declines to answer, 3-2 (No. 24-166) | Nuisance existence called "a factual issue"; question returns to federal court |
| Oct. 28, 2025 | Fourth Circuit vacates and remands, 157 F.4th 547 | Over-distribution can be a nuisance; money abatement allowed; CSA duties misread |
| May 2026 | Remand hearing before Faber | Farrell urges a "different lens"; defense says nothing has changed |
| Nov. 18, 2026 | Faber's 243-page remand decision | Judgment for distributors again; appeal announced |
What did the Fourth Circuit tell Faber to do on remand?
The Fourth Circuit's Oct. 28, 2025 published opinion, written by Senior Circuit Judge Barbara Milano Keenan and joined by Judges Robert B. King and DeAndrea Gist Benjamin, rejected the legal framework of the 2022 judgment on three fronts, and it did so after the Supreme Court of Appeals of West Virginia declined to answer the certified question in May 2025.
- Public nuisance scope. The panel held that "under West Virginia common law, the conditions resulting from the over-distribution of opioids can constitute a public nuisance," rejecting Faber's view that nuisance law does not reach the sale or distribution of a product. Keenan described public nuisance under state law as "broadly defined" and called West Virginia "ground zero" for the epidemic.
- Controlled Substances Act duties. The court said Faber misconstrued the distributors' obligations under the Controlled Substances Act, particularly on setting order thresholds and identifying and reporting suspicious orders, and that he did not fully account for evidence that the companies repeatedly raised pharmacy order limits. Commentators summarized the corrected standard as order-by-order monitoring.
- Abatement remedy. The panel held that West Virginia law permits abatement of a public nuisance to include a requirement that a defendant pay money to fund efforts to eliminate the harm, so the $2.5 billion plan could not be dismissed as a disguised damages claim.
Critically, the Fourth Circuit did not enter judgment for the plaintiffs or order a new trial. It vacated the finding that the local governments failed to prove an unreasonable interference with a public right and remanded that question "for determination in the first instance under the correct legal standard," with instructions to revisit causation and, if reached, the abatement plan on its merits. That left the fact-finding to the same judge who had heard the evidence.
Why did the distributors win again under the new standard?
The answer is the distinction between legal error and factual findings. The Fourth Circuit corrected the law: what counts as a nuisance, what the Controlled Substances Act required of a wholesaler and what remedies are available. It did not tell Faber what to find about why so many pills reached Huntington.
On remand, Faber located the cause in the practice of medicine. By finding that overprescribing within a then-prevailing standard of care, rather than illegal prescribing or diversion at the wholesale level, drove the volume, the decision cuts the causal chain between any lapses in suspicious-order monitoring and the community-wide harm. A plaintiff can establish that a distributor's compliance program was deficient and still lose if the fact-finder concludes the pills would have been dispensed anyway on facially legitimate prescriptions. That is a General Causation-style problem transplanted into public nuisance: the defendant's conduct has to be a cause of the condition the plaintiff wants abated.
The same move addresses unreasonableness. A nuisance requires an unreasonable interference, and Faber's "danger of harm" versus "social utility" balancing treats the lawful distribution of FDA-approved medicines, filled on prescriptions written by licensed physicians, as carrying significant social utility. When the volume is attributed to prescribing norms, the wholesaler's role looks less like the source of the harm and more like a conduit for decisions made by others.
Is the Huntington Cabell opioid ruling final, and will it be appealed?
No. Farrell told WV MetroNews that the city and county will appeal "once again" to the Fourth Circuit and that there will be a "third chapter," adding that the fight will continue. A notice of appeal in a federal civil case is generally due within 30 days after entry of judgment under Federal Rule of Appellate Procedure 4(a)(1)(A).
The next appeal will be harder than the last. In 2025 the plaintiffs attacked legal conclusions, which the Fourth Circuit reviewed de novo. This time the decisive findings are factual: what drove the volume, whether diversion occurred while the drugs were under the distributors' control, and whether the conduct was unreasonable. Under Federal Rule of Civil Procedure 52(a)(6), findings from a bench trial are set aside only if clearly erroneous. The plaintiffs' best route is to argue that Faber again applied the wrong legal test, for example by treating CSA compliance as satisfied without the order-by-order analysis the panel described, or by asking for proof of illegal prescribing that the corrected standard does not require. If the panel agrees the findings are infected by legal error, it can vacate again; if not, the clear-error standard will be difficult to overcome.
On the defense side, AmerisourceBergen trial counsel Robert Nicholas described the plaintiffs' proof as "paltry, inaccurate evidence," according to MetroNews. After the 2025 reversal, a Cencora spokesperson said the company was considering further appellate review; the distributors' position on remand was that nothing in the record had changed.
How much money is at stake?
The plaintiffs asked for a 15-year abatement program valued at about $2.5 billion, which the Fourth Circuit's opinion made legally available in principle. Some accounts of closing arguments in 2021 put the requested figure lower, at no less than $1.7 billion based on a city resiliency plan, and earlier filings described it as more than $2 billion. Under the Nov. 18 decision, the amount awarded is zero.
The opportunity cost is also concrete. West Virginia's other cities and counties settled with the same three distributors in 2022 for $400 million paid over 12 years, a deal that sat outside the national $26 billion opioid settlement with the distributors and Johnson & Johnson. Huntington and Cabell County chose to stay in federal court for a bigger recovery and have now lost two trial-level decisions.
| Metric | Figure |
|---|---|
| Abatement plan requested | About $2.5 billion over 15 years |
| Pills alleged shipped, 2006-2014 | About 81 million (disputed by defendants) |
| Population of the area | Fewer than 100,000 |
| West Virginia local-government settlement with Big 3 (2022) | $400 million over 12 years (Huntington and Cabell excluded) |
| National distributor and J&J settlement | $26 billion (West Virginia not included) |
| Length of Fourth Circuit opinion (2025) | 49 pages |
| Length of Faber remand decision (2026) | 243 pages |
| Award after remand | $0 |
Does the ruling affect other opioid public nuisance cases?
Directly, no. A district court's findings of fact on a single trial record bind only the parties. The Fourth Circuit's 2025 statement of West Virginia nuisance law remains the controlling federal reading, and the remand decision did not disturb it.
Indirectly, it reinforces a pattern defendants will cite. Public nuisance has become the main vehicle for government opioid claims, and the scorecard is divided. The Oklahoma Supreme Court reversed a $465 million judgment against Johnson & Johnson in 2021, and the Ohio Supreme Court in December 2024 held that Ohio's product liability statute abrogates public nuisance claims for product sales, erasing a pharmacy abatement award won by Lake and Trumbull counties in MDL No. 2804. On the other side, the Alaska Supreme Court reinstated that state's nuisance claim against Albertsons and Kroger this month, and a Washington judge ordered Albertsons to pay $900 million in that state's opioid case. Faber's decision adds a different kind of defense win: the law permits the claim, but the plaintiff loses on causation and reasonableness at trial.
For counsel still litigating opioid claims against distributors, pharmacies or pharmacy benefit managers, the lesson is that proving monitoring failures is not enough without evidence tying those failures to diversion that reached the plaintiff community.
What it means for plaintiffs' counsel, defendants and governments
Plaintiffs' firms and government clients. The case is a cautionary data point on opting out of a negotiated deal to pursue a trial. Public nuisance abatement cases need a causation record that survives a finding that prescribing norms, not wholesale conduct, drove volume. Expert work linking specific unflagged or unreported orders to diversion into the jurisdiction, and evidence of illegal prescribing by identifiable prescribers, becomes central rather than supplemental. Counsel should also expect remand fact-finding by the same judge and plan the appellate record around legal-standard arguments that avoid clear-error review.
Defendants and their insurers. The decision shows that a favorable appellate statement of law for plaintiffs does not translate automatically into liability. Intervening-cause and standard-of-care evidence, including medical guidance of the period, remains a strong defense even where a court accepts that distribution can be a nuisance and that abatement can be monetary. Defense counsel in other nuisance cases will cite the opinion's balancing of "danger of harm" against "social utility."
Litigation funders and settlement planners. The Huntington and Cabell path, nine years from filing with two trial-level losses, illustrates duration and binary risk in public-entity nuisance litigation. Those risks are part of how holdout claims are valued against global or statewide settlement offers.
Courts and MDL judges. The case is a reminder that remanded bellwethers can take years to resolve after trial, which limits how quickly a single verdict or bench ruling can inform settlement values in a Multidistrict Litigation (MDL).
What happens next in City of Huntington v. AmerisourceBergen?
Expect a notice of appeal from both plaintiffs and briefing in the Fourth Circuit through 2027. The appeal will likely focus on whether Faber followed the panel's mandate on CSA duties and causation. The plaintiffs may also ask that any further remand go to a different judge, a request appellate courts grant sparingly. If the Fourth Circuit affirms, the plaintiffs' remaining option would be a petition for rehearing en banc or for certiorari, neither of which is likely to turn on fact-bound findings.
The full 243-page opinion is on the Southern District of West Virginia docket in City of Huntington v. AmerisourceBergen Drug Corp. (No. 3:17-cv-01362) and the companion Cabell County Commission case.
FAQ
Who won the Huntington Cabell opioid case?
The distributors won. On Nov. 18, 2026, Judge David Faber ruled for AmerisourceBergen (Cencora), McKesson and Cardinal Health, finding Huntington and Cabell County failed to prove a public nuisance.
Why did the judge rule for the opioid distributors again?
Faber found that overprescribing under the evolving medical standard of care, not illegal prescribing or diversion while the drugs were in the distributors' control, drove the volume of opioids, and that the plaintiffs did not prove the companies acted unreasonably.
Didn't the Fourth Circuit rule for Huntington and Cabell County?
Yes, on the law. In October 2025 it held that over-distribution of opioids can be a public nuisance in West Virginia and that abatement can include money, but it left the factual findings on reasonableness and causation to Faber on remand.
How much were Huntington and Cabell County seeking?
About $2.5 billion to fund a 15-year abatement plan for treatment, prevention and recovery services. The remand decision awards nothing.
Will Huntington and Cabell County appeal?
Yes. Lead counsel Paul Farrell said they will appeal to the Fourth Circuit again, where the clear-error standard for bench-trial findings makes reversal harder than in 2025.
Are Huntington and Cabell part of the West Virginia opioid settlement?
No. They were excluded from the $400 million settlement that other West Virginia local governments reached with the Big 3 distributors in 2022 because they chose to litigate their federal case.
Published for legal professionals. Analysis and summaries only — not legal advice, and no attorney-client relationship is created by use of this site.
Read next

Alaska Opioid Lawsuit Against Albertsons and Kroger Revived: State Supreme Court Reinstates Nuisance Claim
On Nov. 6, 2026, a unanimous Alaska Supreme Court reversed the 2024 dismissal of Alaska's opioid lawsuit against Albertsons and Kroger, holding the State stated a public nuisance claim and keeping one slice of its consumer-protection case alive.
Torts Desk · 12 min

Albertsons Opioid Ruling: Washington Judge Orders $900 Million After Nine-Week Bench Trial
On Nov. 5, 2026, King County Superior Court Judge Janet Helson ordered Albertsons and Safeway to pay Washington $900 million: $800 million in abatement and $100 million in Consumer Protection Act penalties. It is the first opioid judgment against the chain and believed to be the largest verdict in state history.
Torts Desk · 12 min

Opioid MDL Co-Lead Counsel: Polster Names Donald Migliori to Succeed the Late Joe Rice
On 23 September 2026 Judge Dan Aaron Polster appointed Motley Rice managing partner Donald Migliori as plaintiffs' co-lead counsel in MDL No. 2804, filling the seat Joe Rice held for eight years before his death on 3 September, just as the PBM phase of the opioid litigation reaches the Sixth Circuit.
Torts Desk · 10 min